Surgical Infections Cost Hospitals Billions. One Under-the-Radar Biotech Player Might be About to Change That

WSW, NY, July 14th, 2026, FinanceWire

Surgical site infections are among the most expensive complications hospitals face. A widely cited analysis using CDC surveillance data identifies them as the largest single contributor to the overall cost of healthcare-associated infections, with an estimated annual cost of $3.3 billion and more than $20,000 in added hospitalization costs per affected admission. Hospitals already work hard to prevent them, using surgical bundles, infection-control protocols, and prophylactic antibiotics. But those antibiotics clear the body within hours, while the wound stays vulnerable to infection for weeks. That gap, between short-duration protection and the long period of actual risk, is where PolyPid (NASDAQ: PYPD) has focused its lead drug, D-PLEX100. The company completed its FDA New Drug Application for the product on June 1, 2026 and potential approval is expected in early 2027.

A recently published study puts hard numbers on what happens when prevention falls short. In a review of 745 colon cancer surgeries at Oulu University Hospital in Finland, postoperative complications accounted for more than a quarter of all hospital spending on these procedures. Patients who developed surgical complications saw costs jump 84% compared to those who recovered cleanly. Cases involving anastomotic leakage, one of the most serious surgical complications tracked, averaged €45,310 in 90-day hospital costs, a 4.4-fold increase compared with uncomplicated recovery. The study tracked hospital-related costs over a full 90 days after surgery, including readmissions and outpatient costs, not just the initial stay, which matters because many complications generate their heaviest costs through readmissions and follow-up care that shorter analyses miss entirely.

When looking at the broader surgical complication problem, infections stand out as one hospitals can target directly. Surgical complications cost significantly more than nonsurgical ones, and patients who developed both types faced costs exceeding €36,000. Surgical site infections, the category that includes wound infections and abscesses, affected 12% of the cohort and ranked among the costliest complications. Unlike a cardiac event, which depends heavily on a patient's underlying health, an infection at the wound site depends substantially on what protection was in place when the incision was closed. That is the variable D-PLEX100 is designed to influence. It is a paste applied directly into the surgical wound before the surgeon closes, releasing the antibiotic doxycycline locally for approximately 30 days using PolyPid's proprietary Kynatrix technology, which builds on its earlier PLEX drug-delivery platform. Those are the kinds of surgical site infections PolyPid designed D-PLEX100 to reduce.

The clinical data is the reason the FDA application carries weight. In the Phase 3 SHIELD II trial, which enrolled 798 patients undergoing abdominal surgery with large incisions, D-PLEX100 reduced the primary composite endpoint of surgical site infections, all-cause mortality, and surgical reinterventions within 30 days by 40% (p=0.0039). It also cut the rate of surgical site infections, a key secondary endpoint, by 60% (p=0.0013). Moreover, D-PLEX100 is applied locally during the procedure before wound closure, rather than requiring a separate post-discharge intervention.

PolyPid announced the completion of its FDA application on June 1, 2026, with a decision expected in the first quarter of 2027. The drug also carries three FDA designations that underscore its priority status: Breakthrough Therapy, Fast Track, and Qualified Infectious Disease Product (QIDP), the last of which can extend applicable US exclusivity periods by five years if the product is approved.

The timing is notable. In the US, a Medicare payment model called TEAM, launched in January 2026, now holds participating hospitals financially responsible for all costs within 30 days of major bowel surgery. Hospitals with the worst surgical-infection rates already face a 1% Medicare payment reduction under the CMS Hospital-Acquired Condition Reduction Program, which includes colon surgery infection measures. And a study published in April 2026 found that cost-effectiveness was consistently the most important factor associated with adoption of infection-prevention practices among surveyed healthcare professionals. A product that reduces surgical infections without changing how surgery is performed seems to speak to all three pressures.

On the commercial side, PolyPid has said US partnership discussions for D-PLEX100 are in late stages. Beyond its lead product, the technology behind D-PLEX100, a layered system that can deliver different drugs at controlled rates for days to months, supports an early-stage pipeline. That pipeline also includes a recently announced long-acting GLP-1 program targeting obesity and diabetes.

The FDA application is filed. The clinical data is in hand. Hospital economics are pushing hard toward prevention. And new research keeps putting a price on the problem D-PLEX100 was designed to address. Approval is not guaranteed, and a successful trial does not assure commercial adoption, but the case for prevention is getting harder to ignore.

Recent News Highlights from Polypid (PYPD)

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

Read this Next >>

NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy (NASDAQ: NXTC) 

Guggenheim Upgrades Eli Lilly Price Target Ahead of Q2 Earnings (NYSE: LLY)

Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from PolyPid Ltd. (the “Issuer”) for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer’s products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer’s public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the Issuer.

Contact